3.77
-0.31 (-7.60%)
| Previous Close | 4.08 |
| Open | 3.97 |
| Volume | 1,362,180 |
| Avg. Volume (3M) | 1,707,962 |
| Market Cap | 269,237,184 |
| Price / Sales | 1.52 |
| Price / Book | 6.37 |
| 52 Weeks Range | |
| Earnings Date | 5 May 2025 - 9 May 2025 |
| Profit Margin | -54.23% |
| Operating Margin (TTM) | -34.45% |
| Diluted EPS (TTM) | -1.32 |
| Quarterly Revenue Growth (YOY) | 83.60% |
| Total Debt/Equity (MRQ) | 208.79% |
| Current Ratio (MRQ) | 2.44 |
| Operating Cash Flow (TTM) | -35.98 M |
| Levered Free Cash Flow (TTM) | -21.69 M |
| Return on Assets (TTM) | -19.38% |
| Return on Equity (TTM) | -144.50% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bearish | Bearish |
| Diagnostics & Research (Global) | Bearish | Bearish | |
| Stock | Neuronetics, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -0.5 |
| Average | 1.13 |
|
Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulations, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Value |
| % Held by Insiders | 9.17% |
| % Held by Institutions | 62.81% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Nkcfo Llc | 31 Mar 2025 | 125,000 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 19 Jun 2025 | Announcement | Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
| 10 Jun 2025 | Announcement | Neuronetics Announces Clinical Presence at the 2025 Clinical TMS Society Annual Meeting and Progress in Greenbrook’s Personalized Care Trial Program |
| 02 Jun 2025 | Announcement | Neuronetics Set to Join Russell 2000® and Russell 3000® Indexes |
| 14 May 2025 | Announcement | Neuronetics Launches First Inaugural National TMS Therapy Awareness Day During Mental Health Awareness Month |
| 06 May 2025 | Announcement | Neuronetics Reports First Quarter 2025 Financial and Operating Results |
| 05 May 2025 | Announcement | Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
| 22 Apr 2025 | Announcement | Neuronetics to Report First Quarter 2025 Financial and Operating Results and Host Conference Call |
| 31 Mar 2025 | Announcement | Evernorth Health Services, a Cigna Company, Expands NeuroStar® TMS Coverage for Adolescents Struggling with Depression |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |